Key terms
About NRBO
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NRBO news
Apr 17
8:07am ET
NeuroBo Pharmaceuticals doses first patient in Phase 1 DA-1726 trial
Apr 12
4:08pm ET
NeuroBo Pharmaceuticals files $150M mixed securities shelf
Mar 13
8:03am ET
NeuroBo Pharmaceuticals cleared to continue Phase 2a trial of DA-1241
Mar 04
8:03am ET
NeuroBo Pharmaceuticals names Marshall Woodworth as CFO
Feb 29
8:08am ET
NeuroBo Pharmaceuticals receives first site IRB approval for obesity trial
Feb 01
8:03am ET
NeuroBo Pharmaceuticals: FDA clears IND application for DA-1726
No recent press releases are available for NRBO
NRBO Financials
Key terms
Ad Feedback
NRBO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NRBO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
